HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates

HeartSciences Inc.

Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.
Net proceeds of $10.3M from stock sales; $1.1M debt converted to equity.
Issued common stock to Mount Sinai for algorithm licenses, recognizing $1.6M intangible asset.
MyoVista Insights cloud-platform beta completed; FDA submission targeted for mid-2025.
MyoVista wav ECG device FDA submission expected in Q1 2025 after final testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.